Skip to main content
News Icon

News categories: Publication

Heinsberg-Study Published

Bonn-based research team determine COVID-19 infection fatality ratein "Heinsberg Study"

The district of Heinsberg in the German state of North Rhine-Westphalia is considered a hot spot for the novel Coronavirus SARS-CoV-2. Following a carnival celebration, the district became one of the first areas in Germany where the pathogen spread and infected large quantities of people. As part of the study, a research team led by Prof. Dr. Hendrik Streeck and Prof. Dr. Gunther Hartmann from the University of Bonn and members of the Cluster of Excellence ImmunoSensation2 carried out a large study to precisely determine the infection fatality rate for the first time among other findings. The results of the study have been pre-published and are now presented to scientists and the public. Publication in a peer-reviewed journal is to follow.

"The results can be used to further improve models on the transmission behavior of the virus. Until now, basis for such data has been relatively uncertain," says co-author Prof. Dr. Gunther Hartmann, Director of the Institute for Clinical Chemistry and Clinical Pharmacology at the University Hospital Bonn and speaker of the Cluster of Excellence, ImmunoSensation2. The study also provides important indicators for further research on SARS-CoV-2 such as: the infection risk dependent on age, gender and pre-existing conditions; the increased severity of illness amidst special circumstances of a massive infection incident such as in Gangelt, or on the risk of infection within families.


Publication

Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event Hendrik Streeck, Bianca Schulte, Beate M. Ku¨mmerer, Enrico Richter, Tobias Höller, Christine Fuhrmann, Eva Bartok, Ramona Dolscheid, Moritz Berger, Lukas Wessendorf, Monika Eschbach-Bludau, Angelika Kellings, Astrid Schwaiger, Martin Coenen, Per Hoffmann, Birgit Stoffel-Wagner, Markus M. Nöthen, Anna-Maria Eis-Hu¨binger, MartinExner, Ricarda Maria Schmithausen, Matthias Schmid and Gunther Hartmann, https://www.medrxiv.org/content/10.1101/2020.05.04.20090076v2


Contact for the media

Dr. Andreas Archut

University Communications

University of Bonn

Phone: +49 (0)228 73-7647

E-Mail: kommunikation@uni-bonn.de

Related news

Bunte Spirale

News categories: Publication

When the map needs an update

Every time we move through a familiar environment, the hippocampus consults an internal map, a detailed spatial representation that is built up through repeated experience. But what happens when something unexpected occurs on a well-known route? Researchers at the UKB and the University of Bonn were able to demonstrate in a mouse model that the brain does not redraw its maps from scratch. Instead, it annotates them: preserving the underlying spatial layout while overlaying new information on top of the existing map. Their findings have now been published in the journal PNAS.
View entry
Dr. Clivia Lisowski und Prof. Christian Kurts

News categories: Publication

Immune cells in the liver help pigeons navigate

How do pigeons find their way home safely over distances of many kilometers? A research team from the University Hospital Bonn (UKB), the University of Bonn, the University of Duisburg-Essen, and the Max Planck Institute for Behavioral Biology has now discovered a previously unknown mechanism: specific immune cells in the liver may help the birds detect the Earth’s magnetic field. The findings have now been published in the journal Science.
View entry
News Icon

News categories: Publication

Twin Lancet Publications Highlight Promising New Approach for Lupus Treatment

A team of international researchers, including ImmunoSensation³ member Prof. Jörg Wenzel, reports promising phase 2 results for enpatoran, a first-in-class oral TLR7/8 inhibitor, in patients with cutaneous and systemic lupus erythematosus (CLE/SLE). In the WILLOW trial, enpatoran significantly improved skin disease activity in a dose-dependent manner and showed favourable safety outcomes. In systemic SLE, treatment also reduced global disease activity and rapidly suppressed the type I interferon gene signature. The twin studies were published in The Lancet and The Lancet Rheumatology.
View entry

Back to the news overview